Published in Tumour Biol on June 11, 2004
Secretion without Golgi. J Cell Biochem (2008) 1.39
Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside? Fibrogenesis Tissue Repair (2011) 1.12
Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients. J Mol Diagn (2011) 0.93
Sensitization of interferon-gamma induced apoptosis in human osteosarcoma cells by extracellular S100A4. BMC Cancer (2004) 0.93
The metastasis-promoting S100A4 protein confers neuroprotection in brain injury. Nat Commun (2012) 0.92
EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. Br J Cancer (2012) 0.88
Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases. Int J Clin Exp Pathol (2008) 0.88
S100 proteins as diagnostic and prognostic markers in colorectal and hepatocellular carcinoma. Hepat Mon (2012) 0.87
Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer (2013) 0.87
Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer. BMC Cancer (2012) 0.82
The metastasis-promoting protein S100A4 regulates mammary branching morphogenesis. Dev Biol (2010) 0.81
The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications. BMC Cancer (2008) 0.81
Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines. PLoS One (2014) 0.80
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft. PLoS One (2014) 0.79
Protein-phospholipid interactions in nonclassical protein secretion: problem and methods of study. Int J Mol Sci (2013) 0.79
Plasma levels of S100A4 in portopulmonary hypertension. Biomarkers (2009) 0.79
Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes. Clin Exp Metastasis (2015) 0.79
Protein folding does not prevent the nonclassical export of FGF1 and S100A13. Biochem Biophys Res Commun (2009) 0.78
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. Cancer Med (2016) 0.77
S100A4 and metastasis: a small actor playing many roles. Am J Pathol (2009) 2.80
The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors. Mod Pathol (2011) 2.08
A man with abdominal pain: enough evidence for surgery? Clin Chem (2012) 2.02
Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.84
Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res (2002) 1.77
Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol (2004) 1.70
Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin Chem (2005) 1.56
Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int J Cancer (2007) 1.53
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer (2010) 1.46
Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines. Cancer Biol Ther (2006) 1.42
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol (2009) 1.37
Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol (2003) 1.36
Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance. BMC Genomics (2003) 1.35
Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res (2005) 1.32
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer (2012) 1.30
Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer (2004) 1.28
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res (2002) 1.26
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res (2003) 1.26
MicroRNAs as biomarkers in colorectal cancer. Am J Pathol (2010) 1.25
Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol (2003) 1.23
Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One (2010) 1.15
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol (2006) 1.13
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer (2002) 1.13
ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res (2012) 1.11
The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev (2002) 1.10
Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. Int J Cancer (2004) 1.07
Patients' medical knowledge and health counseling: what kind of information helps to make communication patient-centered? Patient Educ Couns (2012) 1.07
PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol (2010) 1.06
The war on heterophilic antibody interference. Clin Chem (2005) 1.05
Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes. Int J Cancer (2008) 1.05
Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res (2002) 1.04
Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene (2003) 1.02
Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol (2011) 1.00
N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene (2002) 0.99
Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity. Blood (2011) 0.99
Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res (2005) 0.99
Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res (2003) 0.98
Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol (2004) 0.98
S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis (2003) 0.98
Evolutionary selection pressure and family relationships among connexin genes. Biol Chem (2007) 0.97
Cystatin E/M suppresses legumain activity and invasion of human melanoma. BMC Cancer (2010) 0.97
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med (2007) 0.97
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. Biochem Biophys Res Commun (2005) 0.96
Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study. Scand J Clin Lab Invest (2008) 0.96
Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene (2002) 0.95
Nuclear legumain activity in colorectal cancer. PLoS One (2013) 0.95
The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res (2008) 0.94
Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappaB. BMC Cancer (2010) 0.93
Sensitization of interferon-gamma induced apoptosis in human osteosarcoma cells by extracellular S100A4. BMC Cancer (2004) 0.93
STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer. Cancer Res (2010) 0.93
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int J Cancer (2010) 0.93
Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma. PLoS One (2011) 0.92
Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles. Breast Cancer Res (2011) 0.92
Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells. Pigment Cell Melanoma Res (2010) 0.91
Photochemical internalization: a new tool for drug delivery. Curr Pharm Biotechnol (2007) 0.91
A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. Cancer Immunol Immunother (2010) 0.90
Immunometric assay interference: incidence and prevention. Clin Chem (2002) 0.90
Ischemia induces closure of gap junctional channels and opening of hemichannels in heart-derived cells and tissue. Cell Physiol Biochem (2011) 0.90
In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts. J Magn Reson Imaging (2011) 0.90
Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value. Clin Exp Metastasis (2007) 0.90
Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tumors. J Reprod Med (2010) 0.89
Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer (2004) 0.89
Protease-dependent fractional mass and peptide properties. Eur J Mass Spectrom (Chichester, Eng) (2008) 0.88
Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin Cancer Res (2004) 0.87
Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1. Oncogene (2003) 0.87
Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol (2003) 0.87
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? Radiother Oncol (2007) 0.86
B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer (2014) 0.86
MassSorter: a tool for administrating and analyzing data from mass spectrometry experiments on proteins with known amino acid sequences. BMC Bioinformatics (2006) 0.86
Telomere instability detected in sporadic colon cancers, some showing mutations in a mismatch repair gene. Oncogene (2004) 0.86
AMP-activated protein kinase protects against anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin-induced MA11 breast cancer cell death. Mol Cancer Ther (2006) 0.86
Immunomagnetic detection of micrometastatic cells in bone marrow in uveal melanoma patients. Acta Ophthalmol (2009) 0.85
Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells. Int J Cancer (2002) 0.85
Recovery of gap junctional intercellular communication after phorbol ester treatment requires proteasomal degradation of protein kinase C. Carcinogenesis (2003) 0.85
Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res (2004) 0.85
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination. Angiogenesis (2011) 0.85
Progastrin-releasing peptide: stability in plasma/serum and upper reference limit. Tumour Biol (2008) 0.85
Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype. BMC Cancer (2007) 0.85
Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS. Anal Chem (2014) 0.83
Pancreatic trypsin activates human promatrix metalloproteinase-2. J Mol Biol (2005) 0.83
Mitochondrial microsatellite instability in colorectal carcinomas--frequency and association with nuclear microsatellite instability. Cancer Lett (2005) 0.83
Heterophilic antibody interference in commercial immunoassays; a screening study using paired native and pre-blocked sera. Clin Chem Lab Med (2011) 0.83
Immuno-MS based targeted proteomics: highly specific, sensitive, and reproducible human chorionic gonadotropin determination for clinical diagnostics and doping analysis. Anal Chem (2012) 0.83
Cells heterozygous for the ApcMin mutation have decreased gap junctional intercellular communication and connexin43 level, and reduced microtubule polymerization. Carcinogenesis (2003) 0.83
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies. Int J Cancer (2013) 0.83